Meet us at…
Latest news
OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy. A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy [...]
18 March 2025
Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: Efficacy, cost-effectiveness and future perspectives Background: Chronic, non-healing wounds remain a major challenge for health care practitioners and for society in general, both in terms of the enormous economic burden [...]
18 March 2025
Hanan Osman-Ponchet (1) , Laurie Perdigon (1) , Manon Barthe (1) , Ines Metatla (2) , Kevin Rogers (2) , Ida Chiara Guerrera (2) , Franck Chiappini (3) , Agnes Choppin (3) Pulmonary fibrosis is a progressive lung disease characterized by scarring and stiffening of lung tissue, ultimately leading to [...]
5 November 2024
Nous sommes ravis de présenter, à l'occasion du congrès ESTIV 2024 à Prague, un poster et une présentation orale sur notre projet MAT-PL (ANR-MAT-PL/ANR-22-CE18-0013), en collaboration avec PKDERM, sur "SUCCESSFUL GENERATION OF THREE-DIMENSIONAL HUMAN PRECISION-CUT LUNG SLICES FOR PULMONARY FIBROSIS MODELING". ESTIV_00118[74]
31 May 2024
Abstract: This study aimed to compare incisional wound healing in cats and dogs after the topical application of Manuka honey and a new medical device, Dermapliq. Comparisons were made between each treatment and control, between the two treatments, and between dogs and cats. Twelve cats and twelve dogs were [...]
27 February 2024
Gilbert Zakine, MD, PhD; Anne Perruisseau-Carrier, MD, PhD; Corinne Becker, MD; Frédéric Sedel, MD, PhD; Luc Téot, MD; and Denis Barritault, PhD Abstract Background: CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue [...]
11 April 2023
OTR3 is proud to share a recent publication in the “Aesthetic Surgery Journal Open Forum” from the Oxford University Press concerning “a retrospective self-controlled study evaluating the Prophylactic Effects of our Medical Device Cacipliq 20 on Postsurgical scars.” https://doi.org/10.1093/asjof/ojad031 Aesthetic Surgery Journal Open Forum (ASJOF) is an international award-winning, peer-reviewed, [...]
11 April 2023
OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars
26 January 2023
